Clinical outcomes of everolimus for patients with advanced neuroendocrine tumors arising from the rectum: A singleinstitutional retrospective study

Everolimus (EVE) has been one of standard-of-care for advanced gastrointestinal neuroendocrine tumor (GI-NET) regardless of tumor grade by the results of the RADIANT-4 study enrolling patients with advanced NET G1–2 of GI or lung origin. An unfavorable efficacy in rectal NET was shown in the study (median progression-free survival [PFS] of EVE: 7.4 months in the rectal NET [N=40]). Despite a high incidence of rectal NET in Asian countries, the efficacy of EVE for this population has rarely been reported in the real-world setting.